Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study
Respiratory syncytial virus (RSV) is a leading cause of infant morbidity. France has implemented a national campaign using nirsevimab to prevent RSV-related infections in infants. This study assessed its effectiveness in preventing hospitalization due to bronchiolitis in emergency department (ED). This retrospective study was conducted among six pediatric EDs in the Greater Paris area, France, and included infants aged
Author(s): Marouk Alexis, Verrat Bernadette, Pontais Isabelle, Cojocaru Dumitru, Chappuy Hélène, Craiu Irina, Quagliaro Pauline, Gajdos Vincent, Soussan-Banini Valérie, Gallien Yves, Feral-Pierssens Anne-Laure
Publishing year: 2025
Pages: 229
In relation to
Our latest news
news
Swim Safely by Following the Right Steps
news
Santé publique France Publishes Its 2025 Annual Report: 10 Years of...
news
